David Reive

Partner | Toronto

416.595.8655

Portrait of David Reive

David Reive is a partner and a national leader in intellectual property at Miller Thomson. David primarily practises intellectual property litigation. He represents clients in all types of IP cases and has litigated patent cases involving diverse technology such as oil field equipment, medical devices, software, and pharmaceutical products. He has experience with trademark cases involving food products, footwear, apparel, and benefits programs.

Displaying 1-5 of 5

Miller Thomson lawyers recognized in The Best Lawyers in Canada 2019

In the just released 2019 edition of The Best Lawyers in Canada, 144 Miller Thomson lawyers from across the country have been recognized for their expertise in 47 areas of law. This includes 6 lawyers who were awarded “Lawyer of the Year” in...

More

Miller Thomson lawyers recognized in The Best Lawyers in Canada 2017

126 Miller Thomson lawyers from across the country and in numerous areas of law have been recognized for their expertise in the 2017 edition of The Best Lawyers in Canada. This result is up from 122 lawyers ranked last year....

More

Lexpert recognizes 80 Miller Thomson lawyers

Miller Thomson is pleased to announce 80 lawyers across ten of our offices are recognized in the 2016 edition of The Canadian Legal Lexpert Directory as leading practitioners in their field. Published annually since 1997, The Canadian Legal Lexpert Directory...

More

Miller Thomson recognized in 2014 Best Lawyers in Canada

We are pleased to announce that 80 Miller Thomson lawyers have been recognized in the 2014 edition of Best Lawyers in Canada (this is 15 more lawyers than last year). Seventeen lawyers are new to the list. Additionally, the following lawyers from...

More

David Reive interviewed by CBC on human gene patentability

David Reive is interviewed on CBC Radio on Tuesday, April 16th on the patentability of human genes. David will comment on the United States Supreme Court hearing in The Association for Molecular Pathology v. Myriad Genetics, Inc. The primary issue...

More

Displaying 1-5 of 5
Displaying 1-3 of 3

David Reive speaks on “Framing a Winning Notice of Allegation”

David Reive speaks at the Ontario Bar Association’s Phama and Biosimilar Litigation in Canada program.

More

Miller Thomson lawyers present at 2015 Chief IP Counsel Exchange

Eugene Gierczak presents on the topic of “Designing Competitive IP Strategies for North American and Asian Markets” on September 27. David Reive presents as part of a panel discussion on “The Evolving Landscape in IP Monetization: Innovation will not be Postponed”...

More

David Reive moderates a panel discussion on “Biologics and Biosimilars” at Canadian Institute’s 11th Annual Forum on Pharma Patents.

More

Displaying 1-3 of 3

Sorry. Your search returned no results. Please edit your search criteria and try again.

Displaying 1-3 of 3

Supreme Court of Canada Rules on the Promise of a Patent

On June 30, 2017, the Supreme Court of Canada issued its much awaited decision on the so-called “promise doctrine” of patent utility (AstraZeneca Canada Inc. v. Apotex Inc. 2017 SCC 36).  As applied for many years, the promise doctrine had...

More

David Reive and Karen Durell quoted in The Globe & Mail

The Globe and Mail, "How Canadian companies can protect themselves from fakes, here and abroad"

Sporting a fake down parka that you bought at a flea market may seem like innocent fun, but it’s nothing of the sort to manufacturers and exporters, safety regulators and those whose business depends on protecting intellectual property. It has recently...

More

Experimental Testing in Litigation

The Federal Court has recently issued a practice direction relating to experimental testing for litigation. This practice direction resulted from arguments made in several recent cases to exclude testimony relating to experimental testing where the opposite party was not provided...

More

Displaying 1-3 of 3

Sorry. Your search returned no results. Please edit your search criteria and try again.